TGFBR2 and prostate cancer: Given that analysis of clinical specimens has revealed that TGFβR2 loss is evident in 69% of human prostate cancer-associated stroma and 15% of benign prostate tissue stroma [133], it is likely that not all CAFs are regulated by TGFβ signaling.